Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Safety Study of Galcanezumab in Migraine
2015-001884-38Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of galcanezumab in migraine, sponsored by Eli Lilly and Company. Primary endpoint: Long-term safety and tolerability of LY2951742. Started Oct 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2015-001884-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001884-38.